Bullous Haemorrhagic Vasculitis Associated with Adalimumab in a Child with Juvenile Idiopathic Arthritis

Valeria Biasotti; Dalila Iacono; Chiara Pilotto; Barbara Bigucci; Giorgia Martini

doi:10.2340/actadv.v105.42482

Authors

Valeria Biasotti Pediatric Division, University Hospital S Maria della Misericordia, Udine, Italy
Dalila Iacono Pediatric Division, University Hospital S Maria della Misericordia, Udine, Italy
Chiara Pilotto Pediatric Division, University Hospital S Maria della Misericordia, Udine, Italy
Barbara Bigucci Pediatric Division, Rimini Hospital ASL Romagna, Rimini, Italy
Giorgia Martini Pediatric Division, University Hospital S Maria della Misericordia, Udine, Italy; Department of Medicine, University of Udine, Udine, Italy https://orcid.org/0000-0003-3801-8903

DOI:

https://doi.org/10.2340/actadv.v105.42482

Keywords:

adalimumab, cutaneous vasculitis, Henoch–Schönlein purpura, child, anti-TNF-alpha therapy

Downloads

Download data is not yet available.

References

Mocci G, Marzo M, Papa A, Armuzzi A, Guidi L. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease. J Crohn’s Colitis 2013; 7: 769–779.

https://doi.org/10.1016/j.crohns.2013.01.009 DOI: https://doi.org/10.1016/j.crohns.2013.01.009

Flendrie M, Vissers W, Creemers M, de Jong E, van de Kerkhof P, van Riel P. Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005; 7: R666–R676.

https://doi.org/10.1186/ar1724 DOI: https://doi.org/10.1186/ar1724

Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med 2016; 164: 10–22.

https://doi.org/10.7326/M15-0729 DOI: https://doi.org/10.7326/M15-0729

Hernández MV, Sanmartí R, Cañete JD, Descalzo MA, Alsina M, Carmona L, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthr Care Res 2013; 65: 2024–2031.

https://doi.org/10.1002/acr.22096 DOI: https://doi.org/10.1002/acr.22096

Reinhart JP, Aird JL, Stephens MC, Asch S, Orandi AB, Tollefson MM. Tumor necrosis factor-α inhibitor-induced morphea and psoriasiform dermatitis in a pediatric patient with Crohn’s disease. Pediatr Dermatol 2023; 40: 519–522.

https://doi.org/10.1111/pde.15182 DOI: https://doi.org/10.1111/pde.15182

Eickstaedt JB, Killpack L, Tung J, Davis D, Hand JL, Tollefson MM. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents. Pediatr Dermatol 2017; 34: 253–260.

https://doi.org/10.1111/pde.13081 DOI: https://doi.org/10.1111/pde.13081

Cossio ML, Genois A, Jantchou P, Hatami A, Deslandres C, McCuaig C. Skin manifestations in pediatric patients treated with a TNF-alpha inhibitor for inflammatory bowel disease: a retrospective study. J Cutan Med Surg 2020; 24: 333–339.

https://doi.org/10.1177/1203475420917387 DOI: https://doi.org/10.1177/1203475420917387

Groth D, Perez M, Treat JR, Castelo-Soccio L, Nativ S, Weiss PF, et al. Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients. Pediatr Dermatol 2019; 36: 613–617.

https://doi.org/10.1111/pde.13859 DOI: https://doi.org/10.1111/pde.13859

Marzano AV, Borghi A, Meroni PL, Crosti C, Cugno M. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy. Autoimmunity 2014; 47: 146–153.

https://doi.org/10.3109/08916934.2013.873414 DOI: https://doi.org/10.3109/08916934.2013.873414

Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun 2018; 9: 25.

https://doi.org/10.1038/s41467-017-02466-4 DOI: https://doi.org/10.1038/s41467-017-02466-4

Aeberli D, Seitz M, Jüni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology 2005; 44: 172–175.

https://doi.org/10.1093/rheumatology/keh437 DOI: https://doi.org/10.1093/rheumatology/keh437

Ramos-Casals M, Brito-Zerón P, Cuadrado MJ, Khamashta MA. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr Rheumatol Rep 2008; 10: 442–448.

https://doi.org/10.1007/s11926-008-0072-z DOI: https://doi.org/10.1007/s11926-008-0072-z

Urganci N, Sakar M, Yalcín O, Kalyoncu D. Henoch–Schönlein purpura induced by infliximab for Crohn’s disease: a case report and literature review. Rev Gastroenterol Méx (Engl Ed) 2022; 87: 110–112.

https://doi.org/10.1016/j.rgmxen.2021.10.005 DOI: https://doi.org/10.1016/j.rgmxen.2021.10.005

Rasmussen C, Tisseyre M, Garon-Czmil J, Atzenhoffer M, Guillevin L, Salem JE, et al. Drug-induced IgA vasculitis in children and adults: revisiting drug causality using a dual pharmacovigilance-based approach. Autoimmun Rev 2021; 20: 102707.

https://doi.org/10.1016/j.autrev.2020.102707 DOI: https://doi.org/10.1016/j.autrev.2020.102707

Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor- inhibitors. Mayo Clin Proc 2012; 87: 739–745.

https://doi.org/10.1016/j.mayocp.2012.04.011 DOI: https://doi.org/10.1016/j.mayocp.2012.04.011